已发表的部分文献: 标题:Jumonji Inhibitors Overcome Radioresistance in Cancer through Changes in H3K4 Methylation at Double-Strand Breaks.作者:Bayo J, Tran TA, Wang L, Peña-Llopis S, Das AK, Martinez ED;杂志名称:Cell Rep 标题:A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.作者:Bayo J, Fiore EJ, Dominguez LM, Real A, Malvicini M, Rizzo M, Atorrasagasti C, GarcÃa MG, Argemi J, Martinez ED, Mazzolini GD;杂志名称:J Hepatol 标题:Therapeutic targeting of histone lysine demethylase KDM4B blocks the growth of castration-resistant prostate cancer.作者:Duan L, Chen YA, Liang Y, Chen Z, Lu J, Fang Y, Cao J, Lu J, Zhao H, Pong RC, Hernandez E, Kapur P, Tran TAT, Smith T, Martinez ED, Ahn JM, Hsieh JT, Luo JH, Liu ZP;杂志名称:Biomed Pharmacother 标题:Inhibition of Jumonji demethylases reprograms severe dilated cardiomyopathy and prolongs survival.作者:Tran TA, Zhang QJ, Wang L, Gonzales C, Girard L, May H, Gillette T, Liu ZP, Martinez ED;杂志名称:J Biol Chem 标题:Modulation of the activity of histone lysine methyltransferases and demethylases by curcumin analog in leukaemia cells.作者:Sawesi S, Malkaram SA, Abd Elmageed ZY, Fandy TE;杂志名称:J Cell Mol Med Epigentek 公司是全球领先的表观遗传学相关研究的技术创新者和产品开发供应商。开发了超过700多个专利产品,为表观遗传学方面的研究和新药研发提供全面系统的解决方案,涵盖样品制备、DNA/RNA甲基化(5-mc, 5-hmc, 5-fc, m6A)/DNMT分析、ChIP、组蛋白甲基化/乙酰化/去乙酰化/磷酸化/SUMO-等领域,提供小分子抑制剂、蛋白质、抗体、以及分析试剂盒产品。